



Drug Eluting Coronary Stent
Cobalt Chromium Alloy
Biodegradable Polymer
Biolimus A9
BioMatrix Alpha presents the best in class stent platform design with unique pro-healing coating from the pioneer in abluminal biodegradable technology.
It combines the proven safety of a DES with an abluminal biodegradable polymer, the proven efficacy of BA9™ and an innovative cobalt-chromium stent platform design.
Abluminal coating absorbed after 6 to 9 months
No drug carrier or drug inside the stent
BA9 Designed for Vascular Stent Technologies, optimized for local drug delivery
In the early 2000s the available mTOR inhibitor limus drugs, available for coronary stenting, were developed for systemic application. Biosensors developed its own proprietary limus technology by focusing during the early stages of drug development on its use for vascular technologies.
The Research and Development team developed several versions of Biolimus, through a number of iterations ultimately decided to focus on BA9 (Biolimus A9), as the best option for coronary stent application. Consequently, Biosensors' proprietary limus drug BA9 was used within its BioMatrix DES family and BioFreedom DCS.
BA9 key characteristics
Specifically designed pro-healing polymerNot all polymers are the same
Alpha best-in-class performance vs. other stents
Biosensors International - Biomatrix Alpha Drug Eluting Coronary stent